English C, Aloi JJ. New fda-approved disease-modifying therapies for multiple sclerosis. Clin Ther. 2015;37:691–715.
Article
CAS
PubMed
Google Scholar
Bruck W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013;70:1315–24.
PubMed
Google Scholar
Sormani MP, Bruzzi P. Can we measure long-term treatment effects in multiple sclerosis? Nat Rev Neurol. 2015;11:176–82.
Article
PubMed
Google Scholar
D’Amico E, Leone C, Caserta C, Patti F. Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Rev Neurother. 2015;15:803–24.
Article
PubMed
Google Scholar
Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: What works, what does not, and what is needed. Lancet Neurol. 2015;14:194–207.
Article
PubMed
Google Scholar
Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21:22–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sempere AP, Gimenez-Martinez J. Safety considerations when choosing the appropriate treatment for patients with multiple sclerosis. Expert Opin Drug Saf. 2014;13:1287–9.
Article
PubMed
Google Scholar
Ontaneda D, Cohn S, Fox RJ. Risk stratification and mitigation in multiple sclerosis. Mult Scler Relat Disord. 2014;3:639–49.
Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis-a quiet revolution. Nat Rev Neurol. 2015;11:134–42.
Article
PubMed
PubMed Central
Google Scholar
Sormani MP, De Stefano N. Defining and scoring response to ifn-beta in multiple sclerosis. Nat Rev Neurol. 2013;9:504–12.
Article
CAS
PubMed
Google Scholar
Sormani MP, Rio J, Tintore M, Signori A, Li D, Cornelisse P, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013;19:605–12.
Article
CAS
PubMed
Google Scholar
Freedman MS, Forrestal FG. Canadian treatment optimization recommendations (tor) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the prisms study. Mult Scler. 2008;14:1234–41.
Article
CAS
PubMed
Google Scholar
Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment optimization in ms: Canadian ms working group updated recommendations. Can J Neurol Sci. 2013;40:307–23.
Article
PubMed
Google Scholar
Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol. 2013;73:95–103.
Article
CAS
PubMed
Google Scholar
Prosperini L, Mancinelli CR, De Giglio L, De Angelis F, Barletta V, Pozzilli C. Interferon beta failure predicted by ema criteria or isolated mri activity in multiple sclerosis. Mult Scler. 2014;20:566–76.
Article
CAS
PubMed
Google Scholar
O’Connor PJ, Sperl-Hillen JAM, Johnson PE, Rush WA, Biltz G. Clinical inertia and outpatient medical errors. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in patient safety: from research to implementation (volume 2: Concepts and methodology). Rockville: Agency for Healthcare Research and Quality (US); 2005.
Mohan AV, Phillips LS. Clinical inertia and uncertainty in medicine. JAMA. 2011;306:383. author reply 383–384.
Article
CAS
PubMed
Google Scholar
Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135:825–34.
Article
CAS
PubMed
Google Scholar
Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension. 2006;47:345–51.
Article
CAS
PubMed
Google Scholar
Huang LY, Shau WY, Yeh HL, Chen TT, Hsieh JY, Su S, et al. A model measuring therapeutic inertia and the associated factors among diabetes patients: A nationwide population-based study in taiwan. J Clin Pharmacol. 2015;55:17–24.
Article
CAS
PubMed
Google Scholar
Escobar C, Barrios V, Alonso-Moreno FJ, Llisterri JL, Rodriguez-Roca GC, Prieto MA, et al. New blood pressure control goals, more rational but facilitating therapeutic inertia? J Hypertens. 2013;31:2462.
Article
CAS
PubMed
Google Scholar
Turner BJ, Hollenbeak CS, Weiner M, Ten Have T, Tang SS. Effect of unrelated comorbid conditions on hypertension management. Ann Intern Med. 2008;148:578–86.
Article
PubMed
Google Scholar
Kerr EA, Zikmund-Fisher BJ, Klamerus ML, Subramanian U, Hogan MM, Hofer TP. The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure. Ann Intern Med. 2008;148:717–27.
Article
PubMed
Google Scholar
Glimcher P, Fehr E. Neuroeconomics: decision making and the brain. San Diego: Academic; 2014.
Google Scholar
Croskerry P. The importance of cognitive errors in diagnosis and strategies to minimize them. Acad Med. 2003;78:775–80.
Article
PubMed
Google Scholar
Elstein AS, Schwartz A. Clinical problem solving and diagnostic decision making: selective review of the cognitive literature. BMJ. 2002;324:729–32.
Article
PubMed
PubMed Central
Google Scholar
Reach G. Clinical inertia, uncertainty and individualized guidelines. Diabetes Metab. 2014;40:241–5.
Article
CAS
PubMed
Google Scholar
Ye S. Medical decision making and the counting of uncertainty. Circulation. 2014;129:2500–2.
Article
PubMed
PubMed Central
Google Scholar
Fontana M, Asaria P, Moraldo M, Finegold J, Hassanally K, Manisty CH, et al. Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility. Circulation. 2014;129:2539–46.
Article
PubMed
PubMed Central
Google Scholar
Platt ML, Huettel SA. Risky business: the neuroeconomics of decision making under uncertainty. Nat Neurosci. 2008;11:398–403.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tur C, Tintore M, Vidal-Jordana A, Bichuetti D, Nieto Gonzalez P, Arevalo MJ, et al. Risk acceptance in multiple sclerosis patients on natalizumab treatment. PLoS One. 2013;8:e82796.
Article
PubMed
PubMed Central
Google Scholar
Lee D. Neuroeconomics: Best to go with what you know? Nature. 2006;441:822–3.
Article
CAS
PubMed
Google Scholar
d’Acremont M, Bossaerts P. Decision making: How the brain weighs the evidence. Curr Biol. 2012;22:R808–10.
Article
PubMed
Google Scholar
Saposnik G, Johnston SC. Decision making in acute stroke care: learning from neuroeconomics, neuromarketing, and poker players. Stroke. 2014;45:2144–50.
Article
PubMed
Google Scholar
Ariely D. Predictably irrational: the hidden forces that shape our decisions. New York: HarperCollins Publishers; 2008.
Google Scholar
Hu J, Yu R. The neural correlates of the decoy effect in decisions. Front Behav Neurosci. 2014;8:271.
PubMed
PubMed Central
Google Scholar
Wagner GG, Frick JR, Schupp J, Panel DIfWPDS-Ö. The German socio-economic panel study (soep): scope, evolution and enhancements. Berlin: DIW Berlin; 2007.
Google Scholar
Dohmen T, Falk A, Huffman D, Sunde U, Schupp J, Wagner GG. Individual risk attitudes: measurement, determinants, and behavioral consequences. 2011.
Google Scholar
Panel DIfWPDS-Ö, Sozialforschung TI. Soep 2014 – erhebungsinstrumente 2014 (welle 31) des sozio-oekonomischen panels: Personenfragebogen, altstichproben. Berlin: DIW Berlin / SOEP; 2014.
Google Scholar
Saposnik G, Redelmeier D, Ruff CC, Tobler PN. Cognitive distortions and associated with medical desicions: a systematic review. BMC Med. 2015.
Gerrity MS, DeVellis RF, Earp JA. Physicians’ reactions to uncertainty in patient care. A new measure and new insights. Med Care. 1990;28:724–36.
Article
CAS
PubMed
Google Scholar
Gerrity M, White K, DeVellis R, Dittus R. Physicians’ reactions to uncertainty: refining the constructs and scales. Motiv Emot. 1995;19:175–91.
Article
Google Scholar
Levy I, Snell J, Nelson AJ, Rustichini A, Glimcher PW. Neural representation of subjective value under risk and ambiguity. J Neurophysiol. 2010;103:1036–47.
Article
PubMed
Google Scholar
Anderson LR, Mellor JM. Predicting health behaviors with an experimental measure of risk preference. J Health Econ. 2008;27:1260–74.
Article
PubMed
Google Scholar
David E, Jon K. Information cascades (chapter 16). Cambridge: Cambridge University Press; 2010.
Cesarini D, Sandewall Ö, Johannesson M. Confidence interval estimation tasks and the economics of overconfidence. J Econ Behav Organ. 2006;61:453–70.
Article
Google Scholar
Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14:208–23.
Article
PubMed
PubMed Central
Google Scholar
Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–93.
Article
CAS
PubMed
Google Scholar
Kopke S, Solari A, Khan F, Heesen C, Giordano A. Information provision for people with multiple sclerosis. Cochrane Database Syst Rev. 2014;4:CD008757.
PubMed
Google Scholar
Studdert DM, Mello MM, Sage WM, DesRoches CM, Peugh J, Zapert K, et al. Defensive medicine among high-risk specialist physicians in a volatile malpractice environment. JAMA. 2005;293:2609–17.
Article
CAS
PubMed
Google Scholar
Dijkstra IS, Pols J, Remmelts P, Brand PL. Preparedness for practice: a systematic cross-specialty evaluation of the alignment between postgraduate medical education and independent practice. Med Teach. 2015;37:153–61.
Article
PubMed
Google Scholar
Saposnik G, Redelmeier D, Ruff CC, Tobler PN. Cognitive distortions and associated with medical desicions: a systematic review Med Decis Mak. 2015.
Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, et al. Defining reliable disability outcomes in multiple sclerosis. Brain. 2015;138:3287–98.
Article
PubMed
Google Scholar
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86.
Article
PubMed
PubMed Central
Google Scholar